Latest Oncology News

Novel Oncolytic Immunotherapy Aims to Address Unmet Therapeutic Need for Anti–PD-1 Refractory Tumors

Novel Oncolytic Immunotherapy Aims to Address Unmet Therapeutic Need for Anti–PD-1 Refractory Tumors

January 19th 2022

Brittany Lovely

Investigators have taken strides to genetically engineer novel oncolytic immunotherapies that synergize with existing immunotherapies to maximize antitumor response in anti–PD-1 refractory tumors.

Durvalumab Plus Tremelimumab Improves OS in Unresectable HCC

Durvalumab Plus Tremelimumab Improves OS in Unresectable HCC

January 18th 2022

Caroline Seymour

The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.

Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer

Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer

January 18th 2022

Jessica Hergert

Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.

Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

January 18th 2022

Courtney Marabella

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer.

SIMBA Therapy Encounters Barriers But Holds Promise for Neutropenia and Beyond

SIMBA Therapy Encounters Barriers But Holds Promise for Neutropenia and Beyond

January 18th 2022

Christina T. Loguidice

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Latest Oncology Videos

All Oncology News

FDA Grants Emergency Use Authorization to Long-Acting Antibody Combo for COVID-19 Prevention

January 5th 2022

Kristi Rosa

The long-acting antibody combination of tixagevimab co-packaged with cilgavimab has been granted emergency use authorization in the United States for the pre-exposure prophylaxis of COVID-19.

Bispecific Antibodies Hold Promise in HER2+ Breast Cancer

January 5th 2022

Jessica Hergert

Sara M. Tolaney, MD, MPH, discusses the mechanism of action that makes bispecific antibodies an intriguing approach in managing HER2-positive breast cancer, efficacy data with zanidatamab that were presented during the 2021 SABCS, and her thoughts on sequencing strategies with bispecific antibodies among other agents in the paradigm.

Predominant Lung Cancer Investigator Welcomes a New Era of Research

January 5th 2022

Andrew Smith

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

GlobalData Projects Continued Growth of HER2+ Breast Cancer Market

January 5th 2022

Kyle Doherty

Driven by the anticipated launches of 5 pipeline agents and the label expansions of currently marketed drugs, theHER2-postive breast cancer market is expected to experience low growth from 2020 to 2030.

Applications of FES-PET Imaging in Breast Cancer Treatment Decision-Making

January 5th 2022

Gary Ulaner, MD, PhD

Expert perspective on the applications of FES-PET imaging in treatment decision-making in patients with breast cancer.

Role of FDG-PET Vs FES-PET in ER+ Breast Cancer

January 5th 2022

Gary Ulaner, MD, PhD

Dr Gary Ulaner compares the role of FDG-PET and FES-PET imaging in ER+ Breast Cancer and the ability of each of the 2 techniques in assessing ER status.

Dr. Posner on Leveraging Tipifarnib in HRAS-Mutant Head and Neck Cancer

January 4th 2022

Marshall Posner, MD

Marshall Posner, MD, shares his clinical experience with the use of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Dr. Wirth on the Utility of Tipifarnib in Head and Neck Cancer

January 4th 2022

Lori J. Wirth, MD

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC

January 4th 2022

Courtney Marabella

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer

January 4th 2022

Jessica Hergert

Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.

HRD Status Drives Decisions With Frontline PARP Inhibition in Advanced Ovarian Cancer

January 4th 2022

Caroline Seymour

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

CLN-081 Granted FDA Breakthrough Therapy Designation Status for EGFR-Mutated NSCLC

January 4th 2022

Kristi Rosa

The FDA has granted breakthrough therapy designation to CLN-081 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy.

FDA Grants Rare Pediatric Disease Designation for IMX-110 for Rhabdomyosarcoma

January 4th 2022

Kristi Rosa

The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma.

Chemotherapy-Free Regimens Seek to Replace Current Standards in Metastatic HR+ Breast Cancer

January 4th 2022

Caroline Seymour

Sara Tolaney, MD, MPH, discusses the data with the oral selective estrogen receptor degrader, elacestrant, and the androgen receptor agonist, enobosarm, in estrogen receptor–positive, HER2-negative breast cancer.

The Future of Cancer Care Depends on Trust in the Scientific Community

January 4th 2022

Maurie Markman, MD

Maurie Markman, MD, shares how evidence strongly supports that approaches to cancer prevention have little chance of success unless those being targeted are willing to listen to, and ultimately trust, the recommendations being made by members of the scientific community.

See All News